Table 1 Table 1 Chart 1 Chart 1 Chart 2 Chart 2 Table 2 Table 2All study objectives were met,…
SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the…
ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and…
Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing…
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company engaged…
NEW ORLEANS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF), in partnership with the National Medical Association…
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage…
Results for adults and children ages 6 years and older from INTEGUMENT-OLE long-term extension trial highlight that 46.1% and 51.0%…
OPGx-LCA5 is designed to address vision loss due to Leber congenital amaurosis associated with mutations in the LCA5 gene, which…
DUBLIN, Ireland and BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly…